Have a personal or library account? Click to login
The evolving role of PARP inhibitors in advanced ovarian cancer Cover

The evolving role of PARP inhibitors in advanced ovarian cancer

Forum of Clinical Oncology
Volume 12 (2021): Issue 1 (May 2021)
By: Sofia Levva,  Aglaia Skolariki,  Eleni Sogka,  Alexandros Bokas,  Avraam Assi,  Marianna K. Pispirigou and  Panagiotis Koliou  
Open Access
|Aug 2021

Metrics

DOI: https://doi.org/10.2478/fco-2021-0002 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Journal RSS Feed
Language: English
Page range: 82 - 104
Submitted on: Jan 2, 2021
Accepted on: Feb 18, 2021
Published on: Aug 9, 2021
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
ovarian cancer,
PARP inhibitors,
BRCA mutation,
maintenance treatment,
resistance mechanisms,
homologous recombination deficiency
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology

© 2021 Sofia Levva, Aglaia Skolariki, Eleni Sogka, Alexandros Bokas, Avraam Assi, Marianna K. Pispirigou, Panagiotis Koliou, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 12 (2021): Issue 1 (May 2021)